Healthcare
Zentalis Pharmaceuticals, Inc.(ZNTL)
Live Price
Offline$3.70
+2.21% today
1Y Change
+188.46%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $280.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +18.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zentalis Pharmaceuticals, Inc. (ZNTL) is a Healthcare stock with a market cap of $280.00M and listed on NASDAQ. The stock last traded around $3.70 and up 188.5% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +18.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +18.0%, free cash flow +26.8% with operating margin 0.0% and ROIC -59.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZNTL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +18.0%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -4.4% | -13.3% | -17.8% |
2026 Mar 26, 2026 | -19.5% | -21.3% | -1.5% | +49.1% |
2025 Nov 10, 2025 | +24.5% | +6.1% | +0.0% | +4.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZNTL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZNTL Max Drawdown
-46.75%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZNTL and SPY.
Company Overview
Zentalis Pharmaceuticals, Inc.
NASDAQ Global Market
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
- Leadership
- Julie Eastland
- IPO Date
- Apr 3, 2020
- Employees
- 166
- Street Address
- 1359 Broadway
- Mailing
- New York City, NY, 10018
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 212 433 3791
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.3
Growth
- Revenue
- -100.0%
- EPS
- +18.0%
- Free Cash Flow
- +26.8%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -52.8%
- ROIC
- -59.6%
Balance Sheet
- Debt/Equity
- 0.18
- Current Ratio
- 6.93
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.